Replies to post #2885 on Health Discovery Corp (HDVY)

[ehwest]

ROSG, up 67% on the following diagnostic gene test study.

The bottom line is that there are so far at least 4 gene diagnostic test coming out this year. 2 cancer ovarian tests, 1 cancer lung test and our cancer prostate test. All of these tests are going to make the news and be written up in articles. When they have reliable gene tests, they are that much closer to producing reliable cancer cures. These breakthroughs and recent discoveries where they are finding ways for the body to grow its own healthy organs etc is going to start a new era of fantastic advances which can't be slowed down by some greedy physicians that want to rely on inaccurate testing and massive numbers of unwarranted biopsies. These 4 tests will make a big splash. When the public is aware, they will demand these cancer gene marker oriented tests.

These stocks are real bargains in this marked and trading prices are starting to move. ROSG was up 67% yesterday. VRMLQ was up 6.7% or $1.75

Now is not the time to get discouraged.


ROSG: abstract from Johns Hopkins University School of Medicine

Accurate Classification of Non–Small Cell Lung Carcinoma Using a Novel MicroRNA-Based Approach
Justin A. Bishop1, Hila Benjamin3, Hila Cholakh4, Ayelet Chajut3, Douglas P. Clark1 and William H. Westra1,2
+ Author Affiliations

Authors' Affiliations: Departments of 1Pathology and 2Oncology, The Johns Hopkins Medical Institutions, Baltimore, Maryland; 3Rosetta Genomics Ltd., Rehovot, Israel; and 4Rosetta Genomics, Inc., Philadelphia, Pennsylvania
Corresponding Author:
William H. Westra, The Johns Hopkins University School of Medicine, 401 North Broadway, Weinberg 2242, Baltimore, MD 21231. Phone: [phone]; Fax: [phone]; E-mail: [e-mail].

Abstract
Purpose: Advances in targeted lung cancer therapy now demand accurate classification of non–small cell lung cancer (NSCLC). MicroRNAs (miRNA) are recently discovered short, noncoding genes that play essential roles in tissue differentiation during normal development and tumorigenesis. For example, hsa-miR-205 is a miRNA that is highly expressed in lung squamous cell carcinomas (SqCC) but not in lung adenocarcinomas. The differential expression of miRNAs could be exploited to distinguish these tumor types.

Experimental Design: One hundred and two resected NSCLCs were classified as SqCC or adenocarcinoma based on their histologic features and immunohistochemical profiles. Corresponding preoperative biopsies/aspirates that had been originally diagnosed as poorly differentiated NSCLCs were available for 21 cases. A quantitative reverse transcription-PCR diagnostic assay that measures the expression level of hsa-miR-205 was used to classify the carcinomas as SqCC or adenocarcinoma based solely on expression levels. The two sets of diagnoses were compared.

Results: Using standard pathologic methods of classification (i.e., microscopy and immunohistochemistry), 52 resected lung carcinomas were classified as SqCCs and 50 as adenocarcinomas. There was 100% concordance between the diagnoses established by conventional and miRNA-based methods. MiRNA profiling also correctly classified 20 of the 21 preoperative biopsy specimens.

Conclusions: MiRNA profiling is a highly reliable strategy for classifying NSCLCs. Indeed, classification is consistently accurate even in small biopsies/aspirates of poorly differentiated tumors. Confirmation of its reliability across the full range of tumor grades and specimen types represents an important step toward broad application.